Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Highland Small-Cap Equity Fund Class A (HSZAX)

16.30
Net Asset Value
+0.37%
1 Day
+18.37%
Year-to-Date
Overall Morningstar Rating
Small growth
Style or Category
5.75
Sales Expenses
2.02%
Expense Ratio
Above Average
Morningstar Risk Rating™
Investment Objective The investment seeks long-term growth of capital. The fund seeks to achieve its investment objective by investing at least 80% of its net assets under normal circumstances in equity securities, such as common and preferred stocks, of small-cap companies, plus borrowing for investment purposes. The managers define a small-cap company as one with a market capitalization that falls between (a) the bottom range of the Russell 2000 ® Index ("Russell 2000 Index") and (b) the greater of either the top range of the Russell 2000 Index or $3.0 billion.

Performance

1 month+3.31% 3 years+13.03%
3 months+8.27% 5 years+16.66%
1 year+26.37% Since inception+10.67%
Data through --

Peer Comparisonvs. Small growth

 HSZAXCategory
Performance 5-yr return+16.66%+12.81%
Expense ratio2.02%1.30%
Risk 5 year sharpe ratio1.030.94
Net assets$72.0M$927.0M
Average market cap$1.7B$3.5B
Average P/E19.229.2
Portfolio turnover107%107%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyHighland Funds
Fund manager & tenureJames Dondero / 2 Years
Minimal initial investment$1,000.00
Minimum IRA investment--

Holdings

U.S. stock92.88%
International stock2.93%
Cash2.79%
Fixed income1.40%
Other0.00%
Top 5 Sectors
Portfolio weighting
Industrial materials 15.20%
Healthcare 13.69%
Financial service 12.40%
Consumer goods 10.64%
Business service 9.24%
Top 10 Holdings
Portfolio weighting
JCAP Jernigan Capital Inc6.00%
WTW Weight Watchers International Inc5.13%
IRT Independence Realty Trust Inc4.48%
FINL Finish Line Inc4.31%
VST Vistra Energy Corp3.86%
PDCO Patterson Companies Inc3.69%
PTLA Portola Pharmaceuticals Inc3.43%
PRAH PRA Health Sciences Inc3.35%
RARE Ultragenyx Pharmaceutical Inc2.74%
MOH Molina Healthcare Inc2.37%